SURI Simplify Propel Opportunities ETF
Quote as of Aug 26, 2026 19:43 UTC · Market data delayed approximately 15–20 minutes unless otherwise indicated.
| Previous Close | 20.25 | Day Range | 19.86 – 21.31 |
| 52-Week Range | 14.90 – 21.31 | Volume | 6.79K |
| Avg Volume | 6.54K | AUM | $85.1M (Aug 26, 2026) |
| Expense Ratio | 2.82% | Yield (TTM) | 13.43% |
| NAV | 19.83 | Premium/Discount | +3.23% indicative |
| Inception | Feb 07, 2023 | Holdings | 19 |
| Issuer | Simplify | Exchange | AMEX |
| Category | Biotech | Index Tracked | Not stated in source data |
| CUSIP | 82889N624 | ISIN | US82889N6242 |
| Management | Not stated in source data | ||
About this ETF
The Simplify Propel Opportunities ETF (SURI) aims to deliver substantial long-term capital growth. It achieves this by investing in companies across the biotechnology, pharmaceutical, healthcare technology, and life sciences industries. These particular firms are selected because they are believed to be overlooked by investors, suggesting significant potential for their value to increase. Propel, the fund's sub-advisor, applies its deep scientific and commercial knowledge in health sciences to identify and select the most promising investment opportunities within this sector.
Description from the fund data provider · profile as of Aug 26, 2026.
Price Chart
Daily closing prices (price return, not total return). Comparison lines are normalized to percent change from the range start. Source: Financial Modeling Prep.
Performance
| 1M | 3M | 6M | YTD | 1Y | 3Y* | 5Y* | 10Y* | Incep.* | |
|---|---|---|---|---|---|---|---|---|---|
| Price return | +12.86% | +15.23% | +19.24% | +21.38% | +28.63% | -1.72% | — | — | -5.41% |
| Total return | +12.88% | +19.96% | +29.56% | +31.92% | +51.91% | +14.95% | — | — | +10.53% |
* Annualized. Total return uses the dividend-adjusted price series (distributions reinvested); price return uses unadjusted closes. Performance through Aug 25, 2026. Past performance does not guarantee future results.
Fees
| Net expense ratio | 2.82% | Annual cost of a $10,000 investment | $282.00 |
Illustrative calculation only: expense ratio × $10,000. It excludes trading costs, bid/ask spreads, taxes and changes in investment value. Gross vs. net expense details and any fee waivers are in the prospectus.
Holdings
Holdings as of Aug 22, 2026 — portfolio reporting date from the data provider; holdings are not live positions. 39 rows in database.
| # | Holding | Ticker | Weight | Shares | Market Value |
|---|---|---|---|---|---|
| 1 | PLAINS GP HLDGS L P | PAGP | 40.15% | 1.27M | $34.2M |
| 2 | ACHIEVE LIFE SCIENCES INC USD 0.001 | ACHV | 13.45% | 1.43M | $11.4M |
| 3 | ACHIEVE LIFE SCIENCES I WTS 30JUN30 | — | 5.67% | 966.67K | $4.8M |
| 4 | DELCATH SYS INC USD 0.01 | DCTH | 5.26% | 261.13K | $4.5M |
| 5 | MILESTONE PHARMACEUTICALS INC NPV | MIST | 4.15% | 3.35M | $3.5M |
| 6 | CORCEPT THERAPEUTICS INC USD 0.001 | CORT | 3.80% | 26.43K | $3.2M |
| 7 | PHATHOM PHARMACEUTICALS USD 0.0001 | PHAT | 2.60% | 249.27K | $2.2M |
| 8 | COLLEGIUM PHARMACEUTICAL USD 0.001 | COLL | 2.58% | 80.89K | $2.2M |
| 9 | CELLDEX THERAPEUTICS INC USD 0.001 | CLDX | 2.52% | 53.13K | $2.1M |
| 10 | ABEONA THERAPEUTICS INC USD 0.01 | ABEO | 1.98% | 276.33K | $1.7M |
| 11 | KYVERNA THERAPEUTICS IN USD 0.00001 | KYTX | 1.81% | 182.60K | $1.5M |
| 12 | COMPASS PATHWAYS PLC USD 0.008 ADR | CMPS | 1.79% | 114.28K | $1.5M |
| 13 | INVENTIVA SA NPV ADR | IVA | 1.72% | 313.48K | $1.5M |
| 14 | AQUESTIVE THERAPEUTICS IN USD 0.001 | AQST | 1.53% | 278.72K | $1.3M |
| 15 | ORCHESTRA BIOMED HLDGS I USD 0.0001 | OBIO | 1.38% | 219.39K | $1.2M |
| 16 | LEONABIO INC USD 0.0001 | LONA | 1.35% | 149.28K | $1.1M |
| 17 | ACHIEVE LIFE SCIENCES WTS | — | 1.30% | 247.59K | $1.1M |
| 18 | ARTIVA BIOTHERAPEUTICS I USD 0.0001 | ARTV | 1.30% | 101.36K | $1.1M |
| 19 | PALISADE BIO INC USD 0.01 | PALI | 1.07% | 434.33K | $912.1K |
| 20 | OCULAR THERAPEUTIX INC USD 0.0001 | OCUL | 1.06% | 81.05K | $898.0K |
| 21 | TELSAT 5.625 12/06/26 144A Corp | — | 1.01% | 1.00M | $855.0K |
| 22 | IMMUNIC INC USD 0.0001 | IMUX | 0.60% | 30.73K | $507.0K |
| 23 | UPSTREAM BIO INC USD 0.001 | UPB | 0.51% | 62.11K | $432.9K |
| 24 | AKERO THERAPEUTICS INC CVR | — | 0.50% | 145.61K | $426.6K |
| 25 | SAB BIOTHERAPEUTICS INC USD 0.0001 | SABS | 0.47% | 104.85K | $396.3K |
Click a ticker to see every ETF that owns it.
Sector Exposure
Geographic Exposure
Country weights as reported by the data provider. Developed/emerging/frontier labels follow the classification on the Methodology page. Currency hedged: No hedging indicated in the fund name.
Distributions
| Yield (TTM) | 13.43% | Paid (last 12 months) | $2.7200 |
| Frequency | Quarterly | SEC yield | Not provided by our data source — see the issuer page |
| Last ex-date | Jun 25, 2026 | Last payment | $0.6800 (Jun 30, 2026) |
| Growth 1Y | 0.00% | Growth 3Y / 5Y (ann.) | — / — |
| Ex-date | Record | Pay date | Amount |
|---|---|---|---|
| Jun 25, 2026 | Jun 25, 2026 | Jun 30, 2026 | $0.6800 |
| Mar 26, 2026 | Mar 26, 2026 | Mar 31, 2026 | $0.6800 |
| Dec 23, 2025 | Dec 23, 2025 | Dec 31, 2025 | $0.6800 |
| Sep 25, 2025 | Sep 25, 2025 | Sep 30, 2025 | $0.6800 |
| Jun 25, 2025 | Jun 25, 2025 | Jun 30, 2025 | $0.6800 |
| Mar 26, 2025 | Mar 26, 2025 | Mar 31, 2025 | $0.6800 |
| Dec 23, 2024 | Dec 23, 2024 | Dec 31, 2024 | $0.6800 |
| Sep 25, 2024 | Sep 25, 2024 | Sep 30, 2024 | $0.6800 |
| Jun 25, 2024 | Jun 25, 2024 | Jun 28, 2024 | $1.2500 |
| Mar 25, 2024 | Mar 26, 2024 | Mar 28, 2024 | $0.6800 |
| Dec 26, 2023 | Dec 27, 2023 | Dec 29, 2023 | $0.6800 |
| Sep 27, 2023 | Sep 28, 2023 | Sep 29, 2023 | $0.6800 |
Trailing distribution yield = last 12 months of cash ÷ current price. It is NOT the SEC 30-day yield and distributions are not guaranteed to continue. The difference explained →
Risk Statistics
| Volatility 1Y / 3Y | 22.36% / 28.39% | Sharpe 1Y / 3Y | 2.34 / 0.568 |
| Max drawdown 1Y / 3Y | -11.78% / -47.74% | Sortino 1Y | 3.57 |
| Beta vs S&P 500 (3Y) | 0.736 | Correlation vs S&P 500 (1Y) | 0.307 |
| Downside deviation 1Y | 14.63% | Risk-free rate used | 3.72% (3M T-bill, FRED) |
Computed by ETF Explorer from daily dividend-adjusted closes; volatility and drawdown are annualized/period figures; S&P 500 exposure proxied by SPY. As of Aug 26, 2026. Formulas →
Liquidity
| Volume today | 6.79K | Average volume | 6.54K |
| AUM | $85.1M | Premium/Discount | +3.23% |
| Bid/Ask spread | Not provided by our data source. Check your broker's quote screen; spreads are widest at the open and close. | ||
Premium/discount compares the delayed market price with the last reported NAV — an indicative figure, not the official closing premium/discount. How ETF liquidity works →
Fund Flows (estimated)
| Period | Est. net flow | % of starting AUM | AUM start → end |
|---|---|---|---|
| 1 Day | $0.00 | 0.00% | $85.1M → $85.1M |
| 1 Week | $916.0K | +1.10% | $82.9M → $85.1M |
ETF Explorer estimate: change in reported AUM minus the market-move effect, from our own daily snapshots. Not official issuer creation/redemption data.
Official Fund Resources
External links open the issuer's site or SEC EDGAR in a new tab. The prospectus and official documents are always the authoritative source — review them before investing.
Latest News for SURI
No articles mention this fund directly in the last 7 days — showing general ETF coverage.
Guided help: AUM is fund size. The expense ratio is the yearly cost baked into returns. NAV is the value of what the fund owns per share; the market price can sit slightly above (premium) or below (discount) it. Total return assumes distributions were reinvested. Every dataset shows its own as-of date because holdings, assets and quotes update on different schedules.